PMID- 12480812 OWN - NLM STAT- MEDLINE DCOM- 20021220 LR - 20220318 IS - 1524-4571 (Electronic) IS - 0009-7330 (Linking) VI - 91 IP - 12 DP - 2002 Dec 13 TI - Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis. PG - 1119-26 AB - Extracellular matrix (ECM) remodeling after myocardial infarction (MI) is an important determinant of cardiac function. Tumor necrosis factor-alpha (TNF-alpha) and angiotensin (Ang) II levels increase after MI and both factors affect fibroblast functions. The type 1 (AT1) receptor that mediates most Ang II effects is upregulated after MI in cardiac fibroblasts, and there is evidence that this is caused by TNF-alpha. We sought to determine if TNF-alpha-induced AT1 receptor upregulation alters fibroblast responsiveness to Ang II and if this effect differs from direct TNF-alpha effects on fibroblast functions. In cultured neonatal rat cardiac fibroblasts, TNF-alpha reduced cellular [3H]-proline incorporation, increased matrix metalloproteinase-2 (MMP-2) activity and protein, and increased TIMP-1 protein levels. In cardiac fibroblasts with TNF-alpha-induced AT1 receptor upregulation, Ang II-stimulated [3H]proline incorporation and TIMP-1 protein production was approximately 2-fold greater than in nonpretreated fibroblasts. Angiotensin II reduced MMP-2 activity and protein level only in TNF-alpha-pretreated fibroblasts. Angiotensin II effects were inhibited by selective AT1 (but not AT2) receptor blockers. Thus, TNF-alpha-induced AT1 receptor upregulation enhances Ang II-mediated functions that favor fibrosis. These effects are mostly directionally opposite of direct TNF-alpha effects on cardiac fibroblasts. Recognition of multifaceted TNF-alpha effects provides new insights into post-MI ECM remodeling. FAU - Peng, JianFeng AU - Peng J AD - Department of Medicine, Division of Cardiology, University of California, San Diego, Calif, USA. FAU - Gurantz, Devorah AU - Gurantz D FAU - Tran, Van AU - Tran V FAU - Cowling, Randy T AU - Cowling RT FAU - Greenberg, Barry H AU - Greenberg BH LA - eng GR - R01 HL63909/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Circ Res JT - Circulation research JID - 0047103 RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Imidazoles) RN - 0 (Pyridines) RN - 0 (Receptor, Angiotensin, Type 1) RN - 0 (Receptor, Angiotensin, Type 2) RN - 0 (Receptors, Angiotensin) RN - 0 (Tissue Inhibitor of Metalloproteinase-1) RN - 0 (Tumor Necrosis Factor-alpha) RN - 11128-99-7 (Angiotensin II) RN - 130663-39-7 (PD 123319) RN - 9DLQ4CIU6V (Proline) RN - EC 3.4.24.24 (Matrix Metalloproteinase 2) RN - JMS50MPO89 (Losartan) SB - IM MH - Angiotensin II/*metabolism/pharmacology MH - Angiotensin Receptor Antagonists MH - Animals MH - Animals, Newborn MH - Cardiomyopathies/physiopathology MH - Cells, Cultured MH - Dose-Response Relationship, Drug MH - Enzyme Activation/drug effects MH - Extracellular Matrix/metabolism MH - Fibroblasts/cytology/*drug effects/metabolism MH - Fibrosis/etiology/physiopathology MH - Imidazoles/pharmacology MH - Losartan/pharmacology MH - Matrix Metalloproteinase 2/metabolism MH - Proline/metabolism/pharmacokinetics MH - Pyridines/pharmacology MH - Rats MH - Rats, Sprague-Dawley MH - Receptor, Angiotensin, Type 1 MH - Receptor, Angiotensin, Type 2 MH - Receptors, Angiotensin/*metabolism MH - Tissue Inhibitor of Metalloproteinase-1/metabolism MH - Tumor Necrosis Factor-alpha/*pharmacology MH - Up-Regulation/*drug effects EDAT- 2002/12/14 04:00 MHDA- 2002/12/21 04:00 CRDT- 2002/12/14 04:00 PHST- 2002/12/14 04:00 [pubmed] PHST- 2002/12/21 04:00 [medline] PHST- 2002/12/14 04:00 [entrez] AID - 10.1161/01.res.0000047090.08299.d5 [doi] PST - ppublish SO - Circ Res. 2002 Dec 13;91(12):1119-26. doi: 10.1161/01.res.0000047090.08299.d5.